Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings (Nasdaq: HRMY) will present at two healthcare-focused investor conferences next week as the rare-disease drug developer engages with investors amid ongoing efforts to …
Harmony Biosciences Schedules Investor Conference Appearances Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported 17% first-quarter revenue growth for its narcolepsy drug WAKIX while advancing patent litigation, new formulations and pipeline programs aimed …
Harmony Revenue Rises as WAKIX Franchise Expands Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will report first-quarter 2026 financial results on Thursday, May 7, 2026, before the opening of U.S. financial markets.
Harmony Biosciences Schedules First-Quarter Earnings Call for May 7 Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently appointed Glenn Reicin as chief financial officer, effective immediately, and reaffirmed its 2026 net product revenue guidance of $1.0 …
Harmony Biosciences Appoints Glenn Reicin as CFO, Reaffirms Outlook Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) appointed Peter Anastasiou as chief operating officer and named Troy Ignelzi to its board of directors, while nominating Geno J. …
Harmony Biosciences Appoints COO, Updates Board Membership Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at …
Harmony Biosciences to Present at Needham Healthcare Conference Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported $243.8 million in fourth-quarter 2025 revenue and $868.5 million in full-year net product revenue from its narcolepsy drug WAKIX, …
Harmony Biosciences Reports 2025 Revenue Growth, Issues 2026 Outlook Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) said the U.S. Food and Drug Administration has approved a supplemental new drug application for WAKIX (pitolisant) tablets to treat cataplexy in …
FDA Approves Harmony’s WAKIX for Pediatric Cataplexy Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) said it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before U.S. …
Harmony Biosciences to Report Q4 and Full-Year 2025 Results Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) said preliminary, unaudited net product revenue for its lead narcolepsy drug WAKIX reached approximately $868 million in 2025, setting the …
Harmony’s WAKIX Surges Toward Blockbuster Status as Revenue Nears $1 Billion Read More